1243P - Dacomitinib (D) versus erlotinib (E) in 2nd/3rd line NSCLC: Outcome for Asian patients from the ARCHER 1009 global Phase 3 trial
| Date | 27 September 2014 |
| Event | ESMO 2014 |
| Session | Poster Display session |
| Topics | Anticancer agents Non-Small Cell Lung Cancer Therapy Biological Therapy |
| Presenter | Tony Mok |
| Citation | Annals of Oncology (2014) 25 (suppl_4): iv426-iv470. 10.1093/annonc/mdu349 |
| Authors |
T.S.K. Mok1, K.J. O'Byrne2, S.S. Ramalingam3, P.A. Janne4, M. Boyer5, J.S. Ahn6, H. Zhang7, J. O'Connell8, I. Taylor9, C. Mather10, L. Paz-Ares11
|
Abstract
Aim
Dacomitinib is an irreversible pan-HER kinase inhibitor with activity in advanced NSCLC. In a Phase 2 trial in pt previously treated with chemotherapy, D showed improved PFS compared to E (median PFS 12 .4 weeks vs. 8.3 weeks; HR 0.66, P = 0.0120). A Phase 3 has been completed (Proc ASCO 2014, Abs 8018).
Methods
The ARCHER 1009 trial randomized patients (pt) with locally advanced/metastatic NSCLC following progression with 1 or 2 prior chemotherapy regimens to blinded treatment with D (45 mg PO QD) or E (150 mg PO QD). The primary endpoint was progression-free survival (PFS) per independent review in the co-primary populations [all patients and those with KRAS WT]. Stratification factors were histology, smoking status, ECOG and Asian versus non-Asian/ Indian race.
Results
Of 878 pt enrolled, 174 (20%) were self-designated as Asian.
The PFS per investigator for Asian pt favored D with HR = 0.811 (95% CI: 0.584-1.125, p value, 1-sided = 0.105); median PFS is 3.7 vs 2.8 months in D and E arms respectively. The Response Rate (CR + PR) was 30.3%and 21.2% in D and E respectively with an odds ratio of 1.62 (95% CI: 0.81-3.23). The most common adverse events for D vs E were diarrhea (79.8 vs 65.9%), rash (42.7 vs 42.4%) or dermatitis acneiform (42.7 vs 52.9%) and stomatitis (65.2 vs 41.2 %) and led to discontinuation in 9 pt on D vs 7 on E.
| Dacomitinib (n= 89) | Erlotinib (n= 85) | |
|---|---|---|
| Age, median (range) | 60.4 (38.0-88.8) | 59.1 (40.0-90.0) |
| ECOG 0-1/ 2 (%) | 93.3/6.7 | 94.1/5.9 |
| Male/ female (%) | 67.4/32.6 | 61.2/38.8 |
| Smoker/ non-Smoker (%) | 66.3/33.7 | 64.7/35.3 |
| KRAS wt/ mu/ unknown(%) | 58.4/7.9/33.7 | 68.2/3.5/28.2 |
| EGFR Activating mutation (exon 19, 21 or 18) | 24 (27%) | 20 (23.5%) |
Conclusions
The ARCHER 1009 trial suggested improvement in efficacy for D relative to E in Asian patients. The number of patients with EGFRmu was similar between arms. Treatment discontinuation for drug toxicity was uncommon. Survival data is not mature.
Disclosure
T. Mok: Ad boards: AZ, Roche, Eli Lilly, Merck Serono, Eisai, BMS, AVEO, Pfizer, Taiho, Boehringer-Ingelheim, Novartis, GSK Biologicals, Clovis Oncology, Amgen, Janssen, BioMarin Pharmaceutical; Board of directors: IASLC; Corporate-sponsored research: AZ; K.J. O'Byrne: Advisory boards: Pfizer; Other substantive relationships (Honoraria): Pfizer; S.S. Ramalingam: Advisory boards: Pfizer, AstraZeneca, Genentech; P.A. Janne: Advisory boards: Boehringer-Ingelheim, AstraZeneca, Genentech, Pfizer, Merrimack Pharmaceuticals, Clovis Oncology, Sanofi, Chugai; Stock ownership: Gatekeeper Pharmaceuticals; Other substantive relationships: LabCorp; M. Boyer: Advisory boards: Merck Sharpe & Dohme; Corporate-sponsored research: Pfizer, Boehringer-Ingelheim, Merck Sharpe & Dohme, Peregrine Pharmaceuticals; H. Zhang: Employment and stock ownership: Pfizer; J. O'Connell: Employment and stock ownership: Pfizer; I. Taylor: Employment and stock ownership: Pfizer; C. Mather: Employment and stock ownership: Pfizer; L. Paz-Ares: Advisory boards: Pfizer, BMS. All other authors have declared no conflicts of interest.